Skip to content

Meditation therapy for stomach acidity in OPD

Role of meditation as adjuvant therapy on gastrointestinal quality of life among individuals with functional dyspepsia in an outpatient setting: A randomized pilot trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/02/049643
Enrollment
60
Registered
2023-02-13
Start date
Unknown
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K30- Functional dyspepsia

Interventions

Intervention1: VAM Meditation plus Standard pharmacotherapy: VAM Meditation (30 minutes daily for 8 weeks) plus Standard Pharmacotherpy (Tab Pantoprazole 40 mg PO OD, +/- Tab Amitriptyline 10-25 mg PO

Sponsors

Madhav Banjade
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adult Patients ( >18 years and 2. Normal upper GI endoscopy 3. H. pylori urea breath test Negative 4. Normal routine investigations like CBC, LFT, KFT, ECG, URINE RM, Stool RM, and USG Abdomen.

Exclusion criteria

Exclusion criteria: 1. Dyspepsia with alarm signs: Unintentional weight loss, Dysphagia, Odynophagia, Unexplained weight loss, Iron deficiency anemia, Persistent vomiting, Palpable mass or lymphadenopathy, Family history of upper gastrointestinal cancer. 2. Dyspepsia due to other causes: Dyspepsia secondary to organic disease, Peptic ulcer disease, Gastroesophageal malignancy, Biliary pain, Drug-induced dyspepsia, other causes â?? Celiac disease, chronic pancreatitis, etc. 3. Those undergoing (or recently undergone) colectomy or any major surgeries 4. Bedridden patients and those with critical illness 5. Patients not willing to be a part of the study and willing to provide a written informed consent. 6. Pregnant women.

Design outcomes

Primary

MeasureTime frame
Change in severity and frequency of dyspepsia symptoms in terms of GIQLI score.Timepoint: Baseline, 4 weeks and 8 weeks

Secondary

MeasureTime frame
Changes in HADS score, PSQI score and reduction in the number of medications pre and post intervention.Timepoint: Baseline, 4 weeks and 8 weeks

Countries

India

Contacts

Public ContactMadhav Banjade

AIIMS Rishikesh

anshupathania27@gmail.com8126021556

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026